AstraZeneca Pharmaceuticals LP
NEWS
The FDA’s Oncologic Drugs Advisory Committee (ODAC) has recommended 14-1 that the two companies conduct a trial applicable to the U.S. population.
As AstraZeneca released its 2021 annual financial report, a BBC documentary suggested that the way scientists and politicians politicized its COVID-19 vaccine may have cost lives.
WuXi Biologics was amongst those on the list, with the U.S. stating that it was unable to verify the legitimacy and reliability of the company in its use of U.S. exports.
According to a statement from China’s NHSA, AstraZeneca staff members are suspected of tampering with the genetic testing results of cancer patients in order to defraud medical insurance funds.
Clinical trial news definitely picked up this final week of January. Here’s a look.
BioSpace sat down with Niko Andre, M.D., Ph.D., global franchise head for hematology and immuno-oncology at AstraZeneca.
Last week was a relatively quiet week for clinical trial news, particularly around COVID-19. Here’s a look.
The San Diego-based immunology company is locating and developing molecules where the mechanism of action has either been proven or makes sense.
AstraZeneca has been struggling to find an effective use for its anti-CTLA-4 antibody tremelimumab. It may have finally found it.
JOBS
IN THE PRESS